| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56541df79a26070c6c2c585b54af47c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1a48b04f986c44c2ca9129ce0b1d17c6 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4737
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2030-8813
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-2871
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-325
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-324 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-232
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-202 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N30-88 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-232 |
| filingDate |
2013-05-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f4fde15d5836569737ab736eb01e8484
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_beb372814131eab1ff155f8e4dd918a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4d8e37b11d33b491598df9834cb65a37 |
| publicationDate |
2017-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9700538-B2 |
| titleOfInvention |
Cardiovascular disease primary prevention agent for patients having high blood levels of high-sensitivity C-reactive protein |
| abstract |
The present invention provides the following: a cardiovascular disease primary prevention agent, which comprises as the active ingredient at least one selected from the group consisting of EPA, salts thereof, and esters thereof and is for lowering the risk of cardiovascular disease by administration to subjects having a blood (serum or plasma) hs-CRP level of 1.0 mg/L or higher in spite of no history of cardiovascular disease; a combination marker comprising the blood hs-CRP value and serum EPA/AA ratio for evaluating the primary risk of cardiovascular disease in subjects having no history of cardiovascular disease; and a method for extracting subjects with high risk of cardiovascular disease and/or a method for preventing cardiovascular disease. |
| priorityDate |
2012-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |